Participation of Pregnant Women in Clinical Trials: Will They Participate and Why?

ABSTRACT

The objective of this study is to investigate the willingness of pregnant women to participate in a randomized placebo-controlled clinical trial, and to explore the determinants of their decision making. Cross-sectional survey with semistructured interview and thematic content analysis of pregnant women in a tiertiary care obstetric outpatient clinic. Among the 50 women surveyed, 37 (74%; 95% confidence interval, 60-85%) indicated that they would be willing to participate in a randomized placebo-controlled trial of an injectable medicine given throughout pregnancy, while 5/50 (10%; 95% confidence interval, 3-22%) would decline to participate. Potential benefit to the health of the fetus was ranked as the most important determinant for willingness to participate (68%), followed by benefit to personal health (27%), and altruism (5%). A majority of pregnant women would be willing to participate in a randomized placebo-controlled clinical trial. Pregnant women appear to be willing to accept risks to themselves, if there is a chance that participation in a clinical trial would help their pregnancy and improve their baby's health.

KEYWORDS

Pregnancy - clinical trials - participation

REFERENCES

• 1 Bush J K. The industry perspective on the inclusion of women in clinical trials.  Acad Med . 1994;  69 708-715
• 2 US Congress. National Institutes of Health Revitilization Amendment. Public Law 103-43. 6-10-1993
• 3 Hilts P J. FDA ends ban on women in drug testing. New York Times. March 25, 1993: B8
• 4 Robertson J. Ethical issues related to the inclusion of pregnant women in clinical trials (I). In: Mastroianni AC, Faden R, Federman D, eds., Vol 2. Washington D.C.: National Academy Press 1994: 18-22
• 5 Steinbock B. Ethical issues related to the inclusion of pregnant women in clinical trials (II). In: Mastroianni AC, Faden R, Federman D, eds. Vol 2. Washington DC: National Academy Press 1994: 23-27
• 6 Connor E M, Sperling R S, Gelber R, Kiselev P, Scott G, O'Sullivan M J. et al . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group [see comments].  N Engl J Med . 1994;  331 1173-1180
• 7 Herz S E. Don't test, do sell: legal implications of inclusion and exclusion of women in clinical drug trials.  Epilepsia . 1997;  38(Suppl)4 S42-S49
• 8 Piper J M, Ray W A, Rosa F W. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.  Obstet Gynecol . 1992;  80 429-432
• 9 Mohanna K, Tunna K. Withholding consent to participate in clinical trials: decisions of pregnant women.  Br J Obstet Gynaecol . 1999;  106 892-897
• 10 Caritis S, Sibai B, Hauth J, Lindheimer M D, Klebanoff M, Thom E. et al . Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units [see comments].  N Engl J Med . 1998;  338 701-705
• 11 CLASP Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 women.  Lancet . 1997;  343 619-629
• 12 Levine R J, Hauth J C, Curet L B, Sibai B M, Catalano P M, Morris C D. et al . Trial of calcium to prevent preeclampsia.  N Engl J Med . 1997;  337 69-76
• 13 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ . 1997;  314 253-257
• 14 Sanson B J, Lensing A W, Prins M H, Ginsberg J S, Barkagan Z S, Lavenne-Pardonge E. et al . Safety of low-molecular-weight heparin in pregnancy: a systematic review.  Thromb Haemost . 1999;  81 668-672